BofA downgraded RxSight (RXST) to Underperform from Buy with a price target of $22, down from $36.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight’s Growth Potential Amid Challenges: A Buy Recommendation by David Saxon
- RxSight’s Undervaluation and Growth Potential Justify Buy Rating Despite Revenue Shortfall
- RxSight’s Long-Term Growth Potential Justifies Buy Rating Despite Short-Term Challenges
- RxSight sees Q1 revenue $37.9M, consensus $47.0M
- RxSight cuts FY25 revenue view to $160M-$175M from $185M-$197M